Clinical Trial Update: Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors [Phase 2]

View source ↗

Summary

A Phase II trial of cabozantinib for hepatocellular carcinoma refractory to PD-1 inhibitors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: University of Leipzig | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED